COBAS EGFR MUTATION TEST V2

Somatic Gene Mutation Detection System

FDA Premarket Approval P120019 S007

This medical device record is a pma supplement. A supplement may have changed the device description/function or indication from that approved in the original pma. Be sure to look at the original pma record for more information.

Pre-market Approval Supplement Details

Approval for the cobas® egfr mutation test v2. This device is indicated for:the cobas® egfr mutation test v2 is a real-time pcr test for the qualitative detection of defined mutations of the epidermal growth factor receptor (egfr) gene in dna derived from formalin-fixed paraffin-embedded tumor tissue (ffpet) from non-small cell lung cancer (nsclc) patients. The test is intended to aid in identifying patients with nsclc whose tumors have defined egfr mutations and for whom safety and efficacy of a drug have been established as follows: tarceva® (erlotinib)/exon 19 deletions and l858r and tagrisso® (osimertinib) t790m. Drug safety and efficacy have not been established for the following egfr mutations also detected by the cobas® egfr mutation test v2: tarceva® (erlotinib)/g719x, exon 20 insertions, t790m, s768i and l861q/tagrisso® (osimertinib)/g719x, exon 19 deletions, l858r, exon 20 insertions, s768i, and l861q. For manual sample preparation, ffpet specimens are processed using the cobas® dna sample preparation kit and the cobas z 480 analyzer is used for automated amplification and detection.

DeviceCOBAS EGFR MUTATION TEST V2
Classification NameSomatic Gene Mutation Detection System
Generic NameSomatic Gene Mutation Detection System
ApplicantROCHE
Date Received2015-05-28
Decision Date2015-11-13
Notice Date2015-11-30
PMAP120019
SupplementS007
Product CodeOWD
Docket Number15M-4344
Advisory CommitteePathology
Supplement TypePanel Track
Supplement ReasonLabeling Change - Indications/instructions/shelf Life/tradename
Expedited ReviewYes
Combination Product No
Applicant Address ROCHE 4300 Hacienda Drive po Box 9002 pleasanton, CA 94588
Summary:Summary of Safety and Effectiveness
Labeling: Labeling
Approval Order: Approval Order

Supplemental Filings

Supplement NumberDateSupplement Type
P120019Original Filing
S034 2022-10-21 30-day Notice
S033
S032 2020-07-27 30-day Notice
S031
S030 2019-09-20 30-day Notice
S029 2019-06-27 Real-time Process
S028 2019-04-24 30-day Notice
S027
S026 2018-11-13 30-day Notice
S025 2018-11-09 30-day Notice
S024 2018-08-21 30-day Notice
S023 2018-07-27 30-day Notice
S022 2018-06-08 30-day Notice
S021 2018-06-04 30-day Notice
S020 2018-03-01 30-day Notice
S019 2018-02-23 Normal 180 Day Track
S018 2017-11-30 Normal 180 Day Track
S017 2017-10-30 30-day Notice
S016 2017-10-27 Normal 180 Day Track
S015 2017-09-26 30-day Notice
S014 2017-07-17 30-day Notice
S013 2017-07-14 30-day Notice
S012 2016-09-22 30-day Notice
S011 2016-08-22 30-day Notice
S010 2016-07-08 30-day Notice
S009 2016-04-18 30-day Notice
S008 2015-06-24 30-day Notice
S007 2015-05-28 Panel Track
S006 2015-03-13 30-day Notice
S005 2014-12-19 30-day Notice
S004 2013-12-13 Real-time Process
S003 2013-08-14 30-day Notice
S002 2013-08-09 30-day Notice
S001 2013-07-26 30-day Notice

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.